Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis

Ana Paula Junqueira-Kipnis, Fábio Muniz De Oliveira, Monalisa Martins Trentini, Sangeeta Tiwari, Bing Chen, Danilo Pires Resende, Bruna D S Silva, Mei Chen, Lydia Tesfa, William R. Jacobs, André Kipnis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The development of a new vaccine as a substitute for Bacillus Calmette-Guerin or to improve its efficacy is one of the many World Health Organization goals to control tuberculosis. Mycobacterial vectors have been used successfully in the development of vaccines against tuberculosis. To enhance the potential utility of Mycobacterium smegmatis as a vaccine, it was transformed with a recombinant plasmid containing the partial sequences of the genes Ag85c, MPT51 , and HspX (CMX) from M. tuberculosis. The newly generated recombinant strain mc2-CMX was tested in a murine model of infection. The recombinant vaccine induced specific IgG1 or IgG2a responses to CMX. CD4+ and CD8+ T cells from the lungs and spleen responded ex vivo to CMX, producing IFN-γ, IL17, TNF-α, and IL2. The vaccine thus induced a significant immune response in mice. Mice vaccinated with mc 2-CMX and challenged with M. tuberculosis showed better protection than mice immunized with wild-type M. smegmatis or BCG. To increase the safety and immunogenicity of the CMX antigens, we used a recombinant strain of M. smegmatis, IKE (immune killing evasion), to express CMX. The recombinant vaccine IKE-CMX induced a better protective response than mc2-CMX. The data presented here suggest that the expression of CMX antigens improves the immune response and the protection induced in mice when M. smegmatis is used as vaccine against tuberculosis.

Original languageEnglish (US)
Article numbere78639
JournalPLoS One
Volume8
Issue number11
DOIs
StatePublished - Nov 8 2013

Fingerprint

Mycobacterium smegmatis
Synthetic Vaccines
Mycobacterium tuberculosis
recombinant vaccines
Vaccines
tuberculosis
Tuberculosis Vaccines
vaccines
Immune Evasion
mice
immune response
Mycobacterium bovis
antigens
Mycobacterium bovis BCG
Histocompatibility Antigens Class II
vaccine development
World Health Organization
Antigens
T-cells
Interleukin-2

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis. / Junqueira-Kipnis, Ana Paula; De Oliveira, Fábio Muniz; Trentini, Monalisa Martins; Tiwari, Sangeeta; Chen, Bing; Resende, Danilo Pires; Silva, Bruna D S; Chen, Mei; Tesfa, Lydia; Jacobs, William R.; Kipnis, André.

In: PLoS One, Vol. 8, No. 11, e78639, 08.11.2013.

Research output: Contribution to journalArticle

Junqueira-Kipnis, AP, De Oliveira, FM, Trentini, MM, Tiwari, S, Chen, B, Resende, DP, Silva, BDS, Chen, M, Tesfa, L, Jacobs, WR & Kipnis, A 2013, 'Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis', PLoS One, vol. 8, no. 11, e78639. https://doi.org/10.1371/journal.pone.0078639
Junqueira-Kipnis, Ana Paula ; De Oliveira, Fábio Muniz ; Trentini, Monalisa Martins ; Tiwari, Sangeeta ; Chen, Bing ; Resende, Danilo Pires ; Silva, Bruna D S ; Chen, Mei ; Tesfa, Lydia ; Jacobs, William R. ; Kipnis, André. / Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{0beebfcc425f4ad2b9e1cd0c9d08db82,
title = "Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis",
abstract = "The development of a new vaccine as a substitute for Bacillus Calmette-Guerin or to improve its efficacy is one of the many World Health Organization goals to control tuberculosis. Mycobacterial vectors have been used successfully in the development of vaccines against tuberculosis. To enhance the potential utility of Mycobacterium smegmatis as a vaccine, it was transformed with a recombinant plasmid containing the partial sequences of the genes Ag85c, MPT51 , and HspX (CMX) from M. tuberculosis. The newly generated recombinant strain mc2-CMX was tested in a murine model of infection. The recombinant vaccine induced specific IgG1 or IgG2a responses to CMX. CD4+ and CD8+ T cells from the lungs and spleen responded ex vivo to CMX, producing IFN-γ, IL17, TNF-α, and IL2. The vaccine thus induced a significant immune response in mice. Mice vaccinated with mc 2-CMX and challenged with M. tuberculosis showed better protection than mice immunized with wild-type M. smegmatis or BCG. To increase the safety and immunogenicity of the CMX antigens, we used a recombinant strain of M. smegmatis, IKE (immune killing evasion), to express CMX. The recombinant vaccine IKE-CMX induced a better protective response than mc2-CMX. The data presented here suggest that the expression of CMX antigens improves the immune response and the protection induced in mice when M. smegmatis is used as vaccine against tuberculosis.",
author = "Junqueira-Kipnis, {Ana Paula} and {De Oliveira}, {F{\'a}bio Muniz} and Trentini, {Monalisa Martins} and Sangeeta Tiwari and Bing Chen and Resende, {Danilo Pires} and Silva, {Bruna D S} and Mei Chen and Lydia Tesfa and Jacobs, {William R.} and Andr{\'e} Kipnis",
year = "2013",
month = "11",
day = "8",
doi = "10.1371/journal.pone.0078639",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis

AU - Junqueira-Kipnis, Ana Paula

AU - De Oliveira, Fábio Muniz

AU - Trentini, Monalisa Martins

AU - Tiwari, Sangeeta

AU - Chen, Bing

AU - Resende, Danilo Pires

AU - Silva, Bruna D S

AU - Chen, Mei

AU - Tesfa, Lydia

AU - Jacobs, William R.

AU - Kipnis, André

PY - 2013/11/8

Y1 - 2013/11/8

N2 - The development of a new vaccine as a substitute for Bacillus Calmette-Guerin or to improve its efficacy is one of the many World Health Organization goals to control tuberculosis. Mycobacterial vectors have been used successfully in the development of vaccines against tuberculosis. To enhance the potential utility of Mycobacterium smegmatis as a vaccine, it was transformed with a recombinant plasmid containing the partial sequences of the genes Ag85c, MPT51 , and HspX (CMX) from M. tuberculosis. The newly generated recombinant strain mc2-CMX was tested in a murine model of infection. The recombinant vaccine induced specific IgG1 or IgG2a responses to CMX. CD4+ and CD8+ T cells from the lungs and spleen responded ex vivo to CMX, producing IFN-γ, IL17, TNF-α, and IL2. The vaccine thus induced a significant immune response in mice. Mice vaccinated with mc 2-CMX and challenged with M. tuberculosis showed better protection than mice immunized with wild-type M. smegmatis or BCG. To increase the safety and immunogenicity of the CMX antigens, we used a recombinant strain of M. smegmatis, IKE (immune killing evasion), to express CMX. The recombinant vaccine IKE-CMX induced a better protective response than mc2-CMX. The data presented here suggest that the expression of CMX antigens improves the immune response and the protection induced in mice when M. smegmatis is used as vaccine against tuberculosis.

AB - The development of a new vaccine as a substitute for Bacillus Calmette-Guerin or to improve its efficacy is one of the many World Health Organization goals to control tuberculosis. Mycobacterial vectors have been used successfully in the development of vaccines against tuberculosis. To enhance the potential utility of Mycobacterium smegmatis as a vaccine, it was transformed with a recombinant plasmid containing the partial sequences of the genes Ag85c, MPT51 , and HspX (CMX) from M. tuberculosis. The newly generated recombinant strain mc2-CMX was tested in a murine model of infection. The recombinant vaccine induced specific IgG1 or IgG2a responses to CMX. CD4+ and CD8+ T cells from the lungs and spleen responded ex vivo to CMX, producing IFN-γ, IL17, TNF-α, and IL2. The vaccine thus induced a significant immune response in mice. Mice vaccinated with mc 2-CMX and challenged with M. tuberculosis showed better protection than mice immunized with wild-type M. smegmatis or BCG. To increase the safety and immunogenicity of the CMX antigens, we used a recombinant strain of M. smegmatis, IKE (immune killing evasion), to express CMX. The recombinant vaccine IKE-CMX induced a better protective response than mc2-CMX. The data presented here suggest that the expression of CMX antigens improves the immune response and the protection induced in mice when M. smegmatis is used as vaccine against tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=84892575544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892575544&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0078639

DO - 10.1371/journal.pone.0078639

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e78639

ER -